PARP阻害剤バイオマーカーの市場規模、シェア、動向分析レポート：製品別、サービス別、用途別、地域別、セグメント予測、2024年～2030年

PARP阻害剤バイオマーカー市場の成長と動向：

Grand View Research社の最新レポートによると、世界のPARP阻害剤バイオマーカー市場規模は2030年までに16億210万米ドルに達すると予測され、2024～2030年のCAGRは8.54％で成長すると予測されています。

乳がんの罹患率の上昇は、PARP阻害剤バイオマーカーセグメントの市場拡大の重要な要因です。2022年に発表されたWHOの論文によると、がん患者の有病率は増加しており、推定2,000万人の新規患者と970万人の死亡者が報告されています。進歩にもかかわらず、がんとの闘いは依然として厳しく、診断から5年以内に生存する人は5,350万人と推定されています。さらに、女性乳がんは重大な懸念事項として浮上しており、世界第2位の230万症例（11.6％）を数え、67万人（6.9％）が死亡しています。特に、調査対象となった185カ国中157カ国で、女性の間で最も広く蔓延しています。

ゲノム技術の進歩は、PARP阻害剤のバイオマーカーの開発と改良に大きく貢献しています。2021年8月に発表されたNCBIの論文によると、これらの進歩により、研究者はPARP阻害剤に対する患者の反応を予測するバイオマーカーを同定し、検証することが可能となり、それにより個別化治療戦略が促進されました。高悪性度漿液性卵巣がん（HGSOC）患者において、ポリADPリボースポリメラーゼ阻害剤（PARPis）に対する反応を予測するバイオマーカーを同定する3D機能アッセイを開発した研究があります。このアプローチにより、生理学的に適切な環境において細胞がPARP阻害剤にどのように反応するかを、より正確かつ包括的に理解することができました。

治療と管理のための支出が増加していることが、市場の成長を後押ししています。2022年9月に発表されたBioMed Central Ltdの記事によると、特に乳がんと卵巣がんは、診断の段階、使用される特定の治療法、がん治療に関連する全体的な医療コストなど、いくつかの要因に影響される大きな問題です。提供された情報源は、治療の経済的負担と支出増加の要因に関する洞察を記載しています。乳がんと卵巣がん患者は、治療期間を通じて大きな経済的負担に直面します。

腫瘍治療の経済的負担は大きく、診断段階や治療方法によって大きく異なります。後期と診断された患者は、早期と診断された患者に比べ、一般的に年間と累積の医療費用が高くなります。この傾向はデータからも明らかで、後期と診断された患者の年間平均医療費と累積医療費は顕著に高いです。特に卵巣がんなど様々ながん種でステージIVと診断された場合の累積医療費の大幅な増加は、早期発見の重要性を強調しています。タイムリーな診断により、より効果的な治療が可能になり、患者の転帰の改善や医療費用の削減にも貢献し、市場の成長をさらに後押しします。

PARP阻害剤バイオマーカー市場レポートハイライト

• キットセグメントが2023年に65.35%の最大売上シェアで市場をリードしています。これは、効果的な診断ソリューションに関する意識の高まりによるものです。
• アッセイセグメントは、PARP阻害剤バイオマーカーの開発と検証に不可欠な要素であり、研究者や臨床医が生体サンプル中のバイオマーカー濃度を正確に測定できることから、予測期間中に最も速いCAGRで成長すると予測されています。
• サービス別では、BRCA1&2試験セグメントが2023年に43.54%の最大売上シェアで市場をリードしました。BRCA1とBRCA2変異関連がんに対するPARP阻害剤の重要性の高まりが、その重要性をさらに高めています。
• 用途別では、乳がんセグメントが2023年に48.42%の最大売上シェアで市場をリードしました。卵巣がんセグメントは予測期間中に最も速いCAGRで成長すると予測されています。
• 北米は2023年に43.95%の売上シェアで市場を独占したが、これはゲノム技術の進歩、購買力平価の高さ、質の高い医療に対する政府の支援、新規診断薬の開発資金などの要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 PARP阻害剤バイオマーカー市場の変数、動向、範囲

• 市場系統の展望
  • 親市場展望
  • 関連/補助的な市場展望。
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• PARP阻害剤バイオマーカー市場分析ツール
  • 業界分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 PARP阻害剤バイオマーカー市場：製品別、推定・動向分析

• PARP阻害剤バイオマーカー市場：製品ダッシュボード
• PARP阻害剤バイオマーカー市場：製品変動分析
• PARP阻害剤バイオマーカー市場：製品別収益
• キット
• アッセイ

第5章 PARP阻害剤バイオマーカー市場：サービス別、推定・動向分析

• PARP阻害剤バイオマーカー市場：サービスダッシュボード
• PARP阻害剤バイオマーカー市場：サービス変動分析
• PARP阻害剤バイオマーカー市場：サービス別収益
• BRCA 1と2試験
• HRDテスト
• HRRテスト
• その他

第6章 PARP阻害剤バイオマーカー市場：用途別、推定・動向分析

• PARP阻害剤バイオマーカー市場：用途ダッシュボード
• PARP阻害剤バイオマーカー市場：用途変動分析
• PARP阻害剤バイオマーカー市場：用途別収益
• 乳がん
• 卵巣がん
• その他

第7章 PARP阻害剤バイオマーカー市場：地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 北米
  • 米国
  • カナダ
• 欧州
  • 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア分析、2023年
  • Myriad Genetics, Inc.
  • Ambry Genetics
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • CENTOGENE NV
  • Amoy Diagnostics Co., Ltd.
  • Invitae Corporation
  • NeoGenomics Laboratories.
  • QIAGEN
  • Agilent Technologies, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 3 North America PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 4 North America PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 5 North America PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 6 U.S. PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 7 U.S. PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 8 U.S. PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 9 Canada PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 10 Canada PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 11 Canada PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 12 Europe PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 13 Europe PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 14 Europe PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 15 Europe PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 16 Germany PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 17 Germany PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 18 Germany PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 19 UK PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 20 UK PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 21 UK PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 22 France PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 23 France PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 24 France PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 25 Italy PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 26 Italy PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 27 Italy PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 28 Spain PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 29 Spain PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 30 Spain PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 31 Denmark PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 32 Denmark PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 33 Denmark PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 34 Sweden PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 35 Sweden PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 36 Sweden PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 37 Norway PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 38 Norway PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 39 Norway PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 44 China PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 45 China PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 46 China PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 47 Japan PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 48 Japan PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 49 Japan PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 50 India PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 51 India PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 52 India PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 53 South Korea PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 54 South Korea PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 55 South Korea PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 56 Australia PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 57 Australia PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 58 Australia PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 59 Thailand PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 60 Thailand PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 61 Thailand PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 62 Latin America PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 63 Latin America PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 64 Latin America PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 65 Brazil PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 66 Brazil PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 67 Brazil PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 68 Mexico PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 69 Mexico PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 70 Mexico PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 71 Argentina PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 72 Argentina PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 73 Argentina PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 74 MEA PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 75 MEA PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 76 MEA PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 77 MEA PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 78 South Africa PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 79 South Africa PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 80 South Africa PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 84 UAE PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 85 UAE PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 86 UAE PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 87 Kuwait PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 88 Kuwait PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
• Table 89 Kuwait PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 PARP inhibitor biomarkers market: market outlook
• Fig. 14 PARP inhibitor biomarkers competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook.
• Fig. 17 Industry value chain analysis
• Fig. 18 PARP inhibitor biomarkers market driver impact
• Fig. 19 PARP inhibitor biomarkers market restraint impact
• Fig. 20 PARP inhibitor biomarkers market strategic initiatives analysis
• Fig. 21 PARP inhibitor biomarkers market: Product movement analysis
• Fig. 22 PARP inhibitor biomarkers market: Product outlook and key takeaways
• Fig. 23 Kits market estimates and forecast, 2018 - 2030
• Fig. 24 Assays market estimates and forecast, 2018 - 2030
• Fig. 25 PARP inhibitor biomarkers market: Services movement analysis
• Fig. 26 PARP inhibitor biomarkers market: Services outlook and key takeaways
• Fig. 27 BRCA 1 & 2 Testing market estimates and forecasts, 2018 - 2030
• Fig. 28 HRD Testing market estimates and forecasts,2018 - 2030
• Fig. 29 HRR Testing market estimates and forecasts, 2018 - 2030
• Fig. 30 Others market estimates and forecasts,2018 - 2030
• Fig. 31 PARP inhibitor biomarkers market: Application movement analysis
• Fig. 32 PARP inhibitor biomarkers market: Application outlook and key takeaways
• Fig. 33 Breast Cancer market estimates and forecasts, 2018 - 2030
• Fig. 34 Ovarian Cancer market estimates and forecasts,2018 - 2030
• Fig. 35 Others market estimates and forecasts, 2018 - 2030
• Fig. 36 Global PARP inhibitor biomarkers market: Regional movement analysis
• Fig. 37 Global PARP inhibitor biomarkers market: Regional outlook and key takeaways
• Fig. 38 Global PARP inhibitor biomarkers market share and leading players
• Fig. 39 North America
• Fig. 40 North America market estimates and forecasts, 2018 - 2030
• Fig. 41 U.S. key country dynamics
• Fig. 42 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 43 Canada key country dynamics
• Fig. 44 Canada market estimates and forecasts, 2018 - 2030
• Fig. 45 Europe
• Fig. 46 Europe market estimates and forecasts, 2018 - 2030
• Fig. 47 UK key country dynamics
• Fig. 48 UK market estimates and forecasts, 2018 - 2030
• Fig. 49 Germany key country dynamics
• Fig. 50 Germany market estimates and forecasts, 2018 - 2030
• Fig. 51 France key country dynamics
• Fig. 52 France market estimates and forecasts, 2018 - 2030
• Fig. 53 Italy key country dynamics
• Fig. 54 Italy market estimates and forecasts, 2018 - 2030
• Fig. 55 Spain key country dynamics
• Fig. 56 Spain market estimates and forecasts, 2018 - 2030
• Fig. 57 Denmark key country dynamics
• Fig. 58 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 59 Sweden key country dynamics
• Fig. 60 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 61 Norway key country dynamics
• Fig. 62 Norway market estimates and forecasts, 2018 - 2030
• Fig. 63 Asia Pacific
• Fig. 64 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 65 China key country dynamics
• Fig. 66 China market estimates and forecasts, 2018 - 2030
• Fig. 67 Japan key country dynamics
• Fig. 68 Japan market estimates and forecasts, 2018 - 2030
• Fig. 69 India key country dynamics
• Fig. 70 India market estimates and forecasts, 2018 - 2030
• Fig. 71 Thailand key country dynamics
• Fig. 72 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 73 South Korea key country dynamics
• Fig. 74 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 75 Australia key country dynamics
• Fig. 76 Australia market estimates and forecasts, 2018 - 2030
• Fig. 77 Latin America
• Fig. 78 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 79 Brazil key country dynamics
• Fig. 80 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 81 Mexico key country dynamics
• Fig. 82 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 83 Argentina key country dynamics
• Fig. 84 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 85 Middle East and Africa
• Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 87 South Africa key country dynamics
• Fig. 88 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 89 Saudi Arabia key country dynamics
• Fig. 90 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 91 UAE key country dynamics
• Fig. 92 UAE market estimates and forecasts, 2018 - 2030
• Fig. 93 Kuwait key country dynamics
• Fig. 94 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 95 Market share of key market players - PARP inhibitor biomarkers market

PARP Inhibitor Biomarkers Market Growth & Trends:

The global PARP inhibitor biomarkers market size is anticipated to reach USD 1,602.10 million by 2030 and is projected to grow at a CAGR of 8.54% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of breast cancer is a significant factor for market expansion in the PARP Inhibitors biomarkers sector. According to the WHO article published in 2022, increasing prevalence of cancer cases, with an estimated 20 million new cases of 9.7 million deaths reported. Despite advancements, the fight against cancer remains tough, with an estimated 53.5 million individuals surviving within 5 years of diagnosis. Moreover, Female breast cancer emerges as a significant concern, ranking second in global cases at 2.3 million (11.6%), accounting for 670,000 deaths (6.9%). Especially it stands as the most widespread among women across 157 out of 185 countries surveyed.

Advancements in genomic technologies have significantly contributed to developing and refining PARP inhibitor biomarkers. According to the NCBI article published in August 2021, these advancements have enabled researchers to identify and validate biomarkers that predict patients' response to PARP inhibitors, thereby facilitating personalized treatment strategies. A study developed a 3D functional assay to identify biomarkers predictive of the response to poly-ADP ribose polymerase inhibitors (PARPis) in high-grade serous ovarian cancer (HGSOC) patients. This approach allowed for a more accurate and comprehensive understanding of how cells respond to PARP inhibitors in a physiologically relevant environment.

The increasing expenditure for treatment and management fuels the market growth. According to the articleBioMed Central Ltd published in September 2022, particularly for breast and ovarian cancer, is a major issue influenced by several factors, including the stage of diagnosis, the specific treatments used, and the overall healthcare costs associated with cancer care. The provided sources offer insights into the financial burden of treatments and the factors contributing to their rising expenditure. Breast and ovarian cancer patients face significant financial burdens throughout their treatment journey.

The financial burden of oncology care can be significant and vary widely based on diagnosis stage and treatment methods. Patients diagnosed in later stages generally incur higher annual and cumulative healthcare expenses compared to those diagnosed earlier. This trend is evident in the data, showing notably higher mean annual and cumulative healthcare costs for patients diagnosed at later stages. The considerable rise in cumulative costs, particularly for stage IV diagnoses across various cancer types such as ovarian, emphasizes the critical importance of early detection. Timely diagnosis allows more effective treatment and also contributes to better patient outcomes and reduced healthcare expenditures further propelling market growth.

PARP Inhibitor Biomarkers Market Report Highlights:

• The kits segment led the market with the largest revenue share of 65.35% in 2023. It is due to attributed of rising the awareness regarding effective diagnostics solutions
• The assays segment is anticipated to grow at the fastest CAGR during the forecast period, owing to being a crucial component for developing and validating PARP inhibitor biomarkers, enabling researchers and clinicians to measure these biomarkers' levels in biological samples accurately
• Based on services, the BRCA1 & 2 testing segment led the market with the largest revenue share of 43.54% in 2023, due to its critical role in treatment. The rise in importance of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers has further boosted its significance
• In terms of application, the breast cancer segment led the market with the largest revenue share of 48.42% in 2023. The ovarian cancer segment is anticipated to grow at the fastest CAGR during the forecast period
• North America dominated the market with the revenue share of 43.95% in 2023, owing to factors such as advancement in genomic technologies, high purchasing power parity, government support for quality healthcare, and funding for development of novel diagnostics

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Services
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Services outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. PARP Inhibitor Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of breast cancer
    • 3.2.1.2. Advancements in genomic technologies
    • 3.2.1.3. Rising expenditure for cancer treatment
    • 3.2.1.4. Growing adoption of personalized medicine and precision therapy
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of PARP inhibitor biomarker test kits and assays
    • 3.2.2.2. Limited awareness and understanding of PARP inhibitors biomarkers
• 3.3. PARP Inhibitor Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. PARP Inhibitor Biomarkers Market: Product Estimates & Trend Analysis

• 4.1. PARP Inhibitor Biomarkers Market: Product Dashboard
• 4.2. PARP Inhibitor Biomarkers Market: Product Movement Analysis
• 4.3. PARP Inhibitor Biomarkers Market by Product Revenue
• 4.4. Kits
  • 4.4.1. Kits Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Assays
  • 4.5.1. Assays Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. PARP Inhibitor Biomarkers Market: Services Estimates & Trend Analysis

• 5.1. PARP Inhibitor Biomarkers Market: Services Dashboard
• 5.2. PARP Inhibitor Biomarkers Market: Services Movement Analysis
• 5.3. PARP Inhibitor Biomarkers Market by Services Revenue
• 5.4. BRCA 1 & 2 Testing
  • 5.4.1. BRCA 1 & 2 Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. HRD Testing
  • 5.5.1. HRD Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. HRR Testing
  • 5.6.1. HRR Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. PARP Inhibitor Biomarkers Market: Application Estimates & Trend Analysis

• 6.1. PARP Inhibitor Biomarkers Market: Application Dashboard
• 6.2. PARP Inhibitor Biomarkers Market: Application Movement Analysis
• 6.3. PARP Inhibitor Biomarkers Market by Application Revenue
• 6.4. Breast Cancer
  • 6.4.1. Breast Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Ovarian Cancer
  • 6.5.1. Ovarian Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. PARP Inhibitor Biomarkers Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. North America
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.9. Denmark
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. Mexico
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. Argentina
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Myriad Genetics, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Ambry Genetics
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Thermo Fisher Scientific Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Illumina, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. CENTOGENE N.V.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Amoy Diagnostics Co., Ltd.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Invitae Corporation
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. NeoGenomics Laboratories.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. QIAGEN
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Agilent Technologies, Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives